Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
0.9899
Dollar change
-0.0001
Percentage change
-0.01
%
Index- P/E- EPS (ttm)-1.66 Insider Own7.66% Shs Outstand41.10M Perf Week-4.82%
Market Cap40.68M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float37.95M Perf Month-2.95%
Income-67.25M PEG- EPS next Q- Inst Own51.57% Short Float0.36% Perf Quarter40.21%
Sales0.00M P/S- EPS this Y- Inst Trans46.20% Short Ratio0.20 Perf Half Y9.75%
Book/sh2.51 P/B0.39 EPS next Y- ROA-45.13% Short Interest0.14M Perf Year2.70%
Cash/sh2.09 P/C0.47 EPS next 5Y- ROE-52.41% 52W Range0.63 - 1.76 Perf YTD11.35%
Dividend Est.- P/FCF- EPS past 5Y- ROI-65.21% 52W High-43.76% Beta1.37
Dividend TTM- Quick Ratio6.04 Sales past 5Y0.00% Gross Margin- 52W Low57.13% ATR (14)0.04
Dividend Ex-Date- Current Ratio6.04 EPS Y/Y TTM3.33% Oper. Margin- RSI (14)34.41 Volatility4.39% 3.97%
Employees215 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price2.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-18.29% Payout- Rel Volume0.30 Prev Close0.99
Sales Surprise- EPS Surprise-17.07% Sales Q/Q- EarningsNov 14 BMO Avg Volume687.77K Price0.99
SMA20-5.82% SMA50-3.53% SMA2006.60% Trades Volume207,251 Change-0.01%
Date Action Analyst Rating Change Price Target Change
Apr-05-24Downgrade Piper Sandler Overweight → Neutral $8 → $2
Apr-26-21Initiated Piper Sandler Overweight $25
Apr-26-21Initiated Oppenheimer Outperform $23
Apr-26-21Initiated JP Morgan Underweight $11
Apr-26-21Initiated Chardan Capital Markets Buy $27
Apr-26-21Initiated BofA Securities Buy $20
Nov-19-24 07:00AM
Nov-14-24 07:00AM
Sep-23-24 09:40AM
Sep-19-24 07:00AM
Aug-14-24 07:00AM
07:00AM Loading…
May-22-24 07:00AM
May-17-24 05:00PM
May-08-24 01:53PM
07:00AM
Apr-04-24 11:53AM
06:45AM
06:30AM
Feb-05-24 07:00AM
Dec-18-23 07:00AM
Nov-13-23 04:30PM
12:30PM Loading…
Oct-24-23 12:30PM
Sep-22-23 04:30PM
09:40AM
Sep-13-23 12:05PM
Sep-06-23 09:40AM
Aug-10-23 11:50AM
Aug-04-23 07:00AM
Jun-12-23 08:00AM
May-21-23 10:03AM
May-10-23 07:15AM
07:00AM
Apr-25-23 06:00PM
07:00AM
Apr-22-23 09:45AM
Apr-17-23 08:00AM
07:00AM Loading…
Mar-07-23 07:00AM
Feb-02-23 09:40AM
Jan-17-23 09:40AM
Dec-20-22 08:30AM
Dec-06-22 06:00AM
Nov-30-22 06:05PM
Nov-22-22 08:00AM
Nov-13-22 07:48AM
Nov-08-22 07:00AM
Nov-01-22 12:00PM
Oct-06-22 08:30AM
Sep-07-22 01:15PM
Aug-31-22 12:53PM
Aug-26-22 01:34PM
Aug-25-22 11:53AM
Aug-24-22 01:33PM
Aug-23-22 01:53PM
Aug-19-22 12:32PM
Aug-16-22 10:09AM
Aug-09-22 07:00AM
Aug-01-22 06:00AM
Jul-21-22 08:00AM
Jun-30-22 08:00AM
Jun-21-22 08:30AM
Jun-06-22 08:40AM
May-10-22 07:00AM
May-09-22 07:00AM
May-04-22 08:00AM
May-03-22 08:00AM
Apr-14-22 11:27AM
Apr-12-22 07:30AM
07:30AM
Apr-05-22 08:00AM
Apr-04-22 08:00AM
Mar-08-22 08:00AM
Mar-01-22 09:00AM
07:02AM
04:00AM
Feb-07-22 07:30AM
Jan-13-22 07:30AM
Dec-28-21 04:09AM
Dec-21-21 08:00AM
Dec-20-21 08:00AM
Dec-09-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 08:15AM
Nov-09-21 08:00AM
Oct-22-21 07:30AM
Oct-12-21 08:00AM
Oct-01-21 08:00AM
Sep-29-21 06:15AM
Sep-02-21 08:30AM
Aug-25-21 08:00AM
Aug-10-21 07:00AM
Jul-26-21 03:00PM
Jul-01-21 08:00AM
04:40AM
Jun-04-21 09:00AM
May-11-21 07:00AM
May-06-21 08:00AM
May-05-21 08:30AM
May-03-21 08:00AM
Apr-10-21 08:30AM
Apr-06-21 04:01PM
Mar-31-21 02:01PM
Mar-30-21 07:00PM
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.